A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.